Amoxycillin 200 mg + Potassium Clavulanate 28.5 mg/5ml
| Composition | Amoxycillin 200 mg + Potassium Clavulanate 28.5 mg/5ml |
|---|---|
| Packing | 30 ml with Water |
| MRP | ₹ 65 |
| Dosage Form | Dry Syrups |
Moxizia-CV Dry Syrup contains Amoxycillin 200 mg and Potassium Clavulanate 28.5 mg per 5 ml — a powerful antibiotic combination that pairs amoxycillin with a beta-lactamase inhibitor to fight bacteria that would otherwise be resistant to amoxycillin alone. This paediatric dry syrup formulation is widely used to treat a broad range of bacterial infections in children.
The clavulanate component in Moxizia-CV shields the amoxycillin from being broken down by resistant bacteria, ensuring the antibiotic remains effective. This makes it a trusted choice for paediatricians when treating middle ear infections, sinusitis, chest infections, and more.
This medicine is commonly used for:
Amoxycillin-Clavulanate oral suspension is indicated for the treatment of bacterial infections caused by susceptible organisms including beta-lactamase-producing strains. Clinical indications include acute otitis media, acute bacterial sinusitis, community-acquired pneumonia, acute exacerbations of chronic bronchitis, uncomplicated urinary tract infections, and skin and soft tissue infections in paediatric patients. The lower-strength 200/28.5 mg per 5 ml formulation is typically used in younger children.
Amoxycillin works by breaking down the protective wall that bacteria build around themselves. Some bacteria try to defend themselves by producing a chemical that destroys amoxycillin — but clavulanate blocks this defence mechanism. Together, they ensure the antibiotic can kill a wider range of bacteria effectively.
Amoxycillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing peptidoglycan cross-linking and causing osmotic lysis. Potassium clavulanate is an irreversible inhibitor of bacterial beta-lactamase enzymes (including class A and some class C beta-lactamases); by acylating the beta-lactamase active site, it protects amoxycillin from enzymatic degradation, thereby extending its spectrum to cover beta-lactamase-producing strains of Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, and Klebsiella pneumoniae.
Clavulanic acid, which forms the basis of clavulanate, was discovered from the bacterium Streptomyces clavuligerus in the 1970s. Its discovery was a landmark moment in infectious disease medicine, enabling the development of antibiotic combinations that could overcome bacterial resistance.
Moxizia-CV Dry Syrup should be given as prescribed by your child's doctor. It is best taken at the start of a meal to reduce the chance of stomach upset and to improve absorption. Always shake the bottle well before measuring each dose and complete the full prescribed course.
Always follow the dosage and schedule advised by your doctor — this is general guidance only.
The most common side effects are diarrhoea, nausea, and stomach upset. Some children may develop a mild skin rash. These effects are usually mild and settle on their own. Tell your doctor if any side effect is severe or persistent, especially if there is severe diarrhoea or signs of an allergic reaction.
Amoxycillin-Clavulanate is too strong for young children and should be avoided.
Amoxycillin-Clavulanate has been extensively studied and used in children for decades. When prescribed at appropriate weight-based doses by a doctor, it is a safe and effective first-line antibiotic for many common paediatric infections.
If one antibiotic syrup did not work, a higher-strength version will definitely work.
Antibiotic effectiveness depends on the specific bacteria causing the infection, not just the dose. A doctor will decide whether a higher strength, a different antibiotic, or further investigation is appropriate based on clinical evaluation.